ALX40-4C antiviral: Began a Phase I/II trial in 40 patients to assess anti-CMV effect by viral load and measures of immune status. Groups of eight patients will

Allelix Biopharmaceuticals Inc. (TSE:AXB), Toronto
Product:

Read the full 62 word article

How to gain access

Continue reading with a
two-week free trial.